Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Sutter

Showing results (151-160 of 179) with videos related to

Pageof 18
Sort By:
Plos One|November 17, 2009
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunizationJoost H C M Kreijtz, Yasemin Suezer, Gerrie de Mutsert, et al.
Human Gene Therapy|September 25, 2003
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trialMassimo Di Nicola, Carmelo Carlo-Stella, Andrea Anichini, et al.
Frontiers in Immunology|March 26, 2026
Immunization with MVA-based vaccines protects K18-hACE2 mice from SARS-CoV-2 infection-associated inflammatory lesions in brainsMałgorzata Rosiak, Sabrina Clever, Eva Leitzen, et al.
Future Microbiology|February 11, 2010
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogensMagdalini Moutaftsi, David C Tscharke, Kerrie Vaughan, et al.
The Journal of Infectious Diseases|September 24, 2014
A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret modelJoost H C M Kreijtz, Lidewij C M Wiersma, Heidi L M De Gruyter, et al.
The Lancet. Infectious Diseases|October 10, 2024
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trialMatthijs P Raadsen, Christine Dahlke, Anahita Fathi, et al.
Scientific Reports|August 19, 2017
Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In VivoArwen F Altenburg, Carolien E van de Sandt, Bobby W S Li, et al.
NPJ Vaccines|January 26, 2024
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansLeonie Mayer, Leonie M Weskamm, Anahita Fathi, et al.
Journal of Virology|March 22, 2002
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replicationTodd M Allen, Lorenzo Mortara, Bianca R Mothé, et al.
Journal of Virology|September 2, 2016
Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceArwen F Altenburg, Carolien E van de Sandt, Stella E van Trierum, et al.
Pageof 18

Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
Plos One|November 17, 2009
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunizationJoost H C M Kreijtz, Yasemin Suezer, Gerrie de Mutsert, et al.
Human Gene Therapy|September 25, 2003
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trialMassimo Di Nicola, Carmelo Carlo-Stella, Andrea Anichini, et al.
Frontiers in Immunology|March 26, 2026
Immunization with MVA-based vaccines protects K18-hACE2 mice from SARS-CoV-2 infection-associated inflammatory lesions in brainsMałgorzata Rosiak, Sabrina Clever, Eva Leitzen, et al.
Future Microbiology|February 11, 2010
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogensMagdalini Moutaftsi, David C Tscharke, Kerrie Vaughan, et al.
The Journal of Infectious Diseases|September 24, 2014
A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret modelJoost H C M Kreijtz, Lidewij C M Wiersma, Heidi L M De Gruyter, et al.
The Lancet. Infectious Diseases|October 10, 2024
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trialMatthijs P Raadsen, Christine Dahlke, Anahita Fathi, et al.
Scientific Reports|August 19, 2017
Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In VivoArwen F Altenburg, Carolien E van de Sandt, Bobby W S Li, et al.
NPJ Vaccines|January 26, 2024
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansLeonie Mayer, Leonie M Weskamm, Anahita Fathi, et al.
Journal of Virology|March 22, 2002
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replicationTodd M Allen, Lorenzo Mortara, Bianca R Mothé, et al.
Journal of Virology|September 2, 2016
Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceArwen F Altenburg, Carolien E van de Sandt, Stella E van Trierum, et al.
Pageof 18